Advancing vaccine adjuvant research for tuberculosis
Award Notice Posted
- Solicitation number
- BAA-DAIT-75N93021R00008
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to University Of Sydney
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N93022C00041 Federal contract award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Place of performance
- United States
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a contract to the University of Sydney on September 27, 2022 for advancing vaccine adjuvant research for tuberculosis. The contract, valued at $13,122,648, will support the University of Sydney's work to develop adjuvants, which are compounds added to vaccines to boost immune response, for tuberculosis vaccines. This award furthers the NIH's mission to advance biomedical research and help prevent and treat infectious diseases like tuberculosis.
Notice text
Awarded contract 75N93022C00041 to UNIVERSITY OF SYDNEY for 13122648.00 on 2022-09-27.
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Award Notice | |
| Advancing vaccine adjuvant research for tuberculosis | Solicitation | |
| Advancing vaccine adjuvant research for tuberculosis | Pre-Solicitation |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity